MDMA in Borderline Personality Disorder

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06683014
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Borderline Personality Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • MDMA — DRUG
    Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

Study Details

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Key Dates

Start date
Sep 5, 2025
Status verified
Jan 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Open-Label MDMA
    Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

Primary Outcome Measure

Change in Self-Reported Social Cognition After 1 Dose of MDMA. [ Time Frame: From baseline (immediately before drug dose) to 2 hours after drug dose on the same day. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Connecticut Mental Health CenterNew HavenConnecticut06519-

Find similar trials in New Haven, CT

By research site
Connecticut Mental Health Center· New Haven, CT

Related Studies